RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Changren Information Technology, a China IT health management company, raised $15 million in a Series A funding round led by an unnamed state-owned enterprise, according to press reports. Founded in 2016, Changren provides health management services for individuals and institutions based on its whole life cycle dynamic physiological big data. The company’s major product, a home medical robot called “Xiaobao,” takes a patient’s vital signs at home, transmits them to a cloud platform, and provides medical guidance (medication, diet, and exercise recommendations) through voice broadcasts or short videos.
Source: China Biotoday